Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc.

CATX·AMEX

$3.60

-1.1%
HealthcareMedical - Devices

Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.

At a Glance

Live Snapshot
Market Cap$278.10M
EPS-1.4000
P/E Ratio-1.97
Earnings Date08/12/2026

catx

Research Development Expenses

Last Annual Value

84.22M

3-Year CAGR

219%

5-Year CAGR

126%

10-Year CAGR

66%

Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc. Competitors Analysis of research-development-expenses

CATX · AMEX
Companyresearch-development-expenses
CAGR 3Y
CAGR 5Y
CAGR 10Y
84.22M
58.1%100.8%56.3% 
14.96M
-20.5%1.0%N/A
996.00K
2.8%-10.4%10.1%
MXCT logo
MaxCyte, Inc.
NASDAQ:MXCT
20.82M
-4.4%6.2%16.1%
IVVD logo
Invivyd, Inc.
NASDAQ:IVVD
38.31M
-37.7%-26.8%N/A
6.58M
-11.6%-3.6%-2.2%
HSDT logo
Solana Company
NASDAQ:HSDT
3.51M
6.1%-10.1%N/A
Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc. Fair Value Envelope

CATX · AMEX

Our analysis suggests that CATX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $3.6, this represents a potential HIDDEN relative to our calculated worth for Perspective Therapeutics, Inc..

Intrinsic Value
Current Price: $3.6